Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BioTransplant, MedImmune Inc., Protein Design Labs Inc deal

BTRN received a sub-license from MEDI for use of PDLI's

Read the full 103 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE